The Line a Cream Cannot Cross

Longevity skincare copy is full of pathway names and short on outcomes. There is a legal reason for that, and knowing it changes how you read a label.

A minimalist composition showcasing a box, cream container, and eucalyptus branch on a white background.

If you have read the back of a longevity serum recently, you may have noticed something strange about the writing.

It is dense with biology. Sirtuins. Senescent cells. Mitochondrial repair. Inflammaging. Epigenetic resetting. These are real terms from real research, and a brand using them is signaling that it has read the literature.

Then you look for what the product is supposed to do to your face, and the sentence is not there. The copy names a pathway and stops.

That pattern is not an accident of style, and it is not brands being coy. There is a specific legal reason for it, and once you know what the reason is, a whole category of packaging becomes much easier to read.

The complaint that prompted this

On 11 November, Fortune published a commentary by Sindhya Valloppillil, a journalist who writes the beauty newsletter Skin Dossier, under the headline that longevity is the beauty industry's most powerful claim and its weakest link.

Her argument is that the industry has borrowed the vocabulary of longevity medicine faster than it has built the evidence to carry it. She points at L'Oréal's Longevity AI Cloud, built on more than 260 biomarkers across the hallmarks of aging, and its Cell BioPrint tape-strip test. At Estée Lauder's Skin Longevity Institute and its Re-Nutriv line repositioned around a patented sirtuin technology. At OneSkin, at Paula's Choice, and at a red light device company referred to regulators in October after it declined to take part in an advertising inquiry.

The line in the piece that matters most is the plainest one. Much of what is marketed as longevity, she writes, "still relies on narrative rather than science."

That is a fair complaint. It is also only half the picture, because the brands are operating inside a constraint that the complaint does not mention.

Where American law draws the line

In the United States, the difference between a cosmetic and a drug turns on what the label says the product is for. The contents of the bottle do not settle it.

A cosmetic is something applied to the body to cleanse, beautify or alter the appearance. A drug is something intended to affect the structure or any function of the body. The claim decides the category, and the ingredient has no say in it.

Follow that through and the copy explains itself. A cream that says it makes skin look smoother has made a cosmetic claim. A cream that says it activates sirtuins has said it intends to change how your cells behave, which is a statement about the function of the body. Todd Harrison, a lawyer at Venable who co-chairs the firm's FDA practice, told Fortune that referencing sirtuin activation, senescent cell clearance or mitochondrial repair "may classify a product as a drug."

A drug needs approval. Approval needs trials. Trials cost years and money that a seasonal skincare launch does not have.

So the brand is caught between two pressures. It needs to sound like it belongs in a serious scientific conversation, because that is the category it is selling into. And it cannot promise the thing that would prove it belongs, because the promise is the part that would reclassify the product.

The resolution is the copy you have been reading. Name the pathway, which sounds like science. Avoid the outcome, which would be a drug claim. The result is a paragraph that is simultaneously impressive and empty.

This has happened before, with a different word

In June 2014, the Federal Trade Commission settled with L'Oréal USA over advertising for Lancôme Génifique and L'Oréal Paris Youth Code.

The ads said Génifique was clinically proven to boost the activity of genes and the production of youth proteins. Youth Code was sold as the arrival of gene science in skincare. The FTC's position was that the company's own testing showed delayed gene expression in aged skin, and that this did not support what the advertising promised.

The settlement was an administrative consent order rather than a court judgment, and it carried no financial penalty. L'Oréal agreed not to make gene-related anti-aging claims without competent and reliable scientific evidence, and said the claims had not been in use for some time.

The regulators had already made the argument of this piece for us, two years earlier and in plain language. In September 2012 the FDA sent a warning letter to Lancôme USA citing claims that a product "boosts the activity of genes" and would "stimulate cell regeneration to reconstruct skin to a denser quality." The agency's conclusion was that such claims indicate the products "are intended to affect the structure or any function of the human body," which under the Federal Food, Drug and Cosmetic Act makes them drugs requiring approval. Marketing them that way, the letter said, violates the act.

That is the whole mechanism, stated by the regulator. Say what the product does to your biology and you have described a drug.

The vocabulary in that case was genetics. Twelve years later the vocabulary is longevity. The structure of the problem has not moved.

What a company-authored review looks like

The November issue of Aging Cell, a respected journal, carries a review titled "Role of Sirtuins in the Hallmarks of Skin Aging."

It has eleven authors. All eleven work for The Estée Lauder Companies, in Melville, New York and at the company's China Innovation Labs in Shanghai. The conflict of interest statement on the record says so in one sentence: all authors are employees of The Estée Lauder Companies. It reached PubMed in the same period the company was building a skin longevity platform that names sirtuins as a master regulator.

The disclosure is worth pausing on, because the honest reading here is less dramatic than it first looks. The company declared the conflict clearly and in the standard place. Nothing was hidden.

Two things are true at once. This is a legitimate scientific document, written by scientists, reviewed by a journal. It is also a marketing asset, in the sense that a peer-reviewed review naming your platform's mechanism is an extremely useful thing to own.

Holding both is the skill. And the detail that decides how much weight to give it is in the abstract: the review walks through thirteen hallmarks of aging and the mechanistic role of sirtuins in each. It describes biology. It does not report what any topical product did to anyone's skin.

The paper never set out to do that, so this is no complaint against it. The caution applies to how such a paper gets used. A review of mechanisms can be entirely accurate about cell biology and still say nothing about whether a cream works.

Expect to see more of this. As the large beauty companies build research institutes around longevity, a peer-reviewed literature will grow around their own platforms, authored by their own scientists, correctly disclosed, and quoted in marketing as independent-sounding support.

How to read the label now

None of this means longevity skincare is fraudulent. It means the copy is written under a constraint, and you can read it better once you know the constraint exists.

Three questions do most of the work.

What is it claiming to do, in plain words? If you cannot find a sentence describing an outcome, that absence is informative. The brand may be avoiding a drug claim, and it may also have no outcome to report.

At what level of biology, and on what timeframe? David Barzilai, a Harvard Medical School lecturer who runs a longevity consultancy and is quoted in the same Fortune piece, suggested that the brands handling this well will say what the product does, at what level of biology, over what period, and with what evidence. That is a reasonable bar to hold a label to.

Was the evidence produced by someone selling the thing? Not disqualifying. The affiliation line and the funding line are at the top and bottom of every paper, and reading them first costs nothing.

And the broader point from our piece on what skin longevity means still applies here. The term had no agreed definition in the scientific literature until 2025. A word that loose is exactly the kind a marketing department can work with, and exactly the kind a regulator eventually gets interested in.

What you can check yourself

While the regulators and the brands settle what the word is allowed to mean, there is one record nobody needs permission to keep.

A cream cannot legally promise you an outcome. You can still look for one. A dated set of photographs of your own face, taken in the same light, twelve weeks apart, is the only longevity result you will get to see on the timescale that any of this is being sold on. It is also the only one that is about you rather than about a pathway.

That is the argument for measuring rather than estimating, and it holds whichever way the regulation goes.

FAQ

Why does longevity skincare name ingredients but not results?

Because of how US law separates cosmetics from drugs. The distinction rests on the claim rather than the ingredient, so a product that promises to change how your cells function has made a drug claim. Naming a pathway sounds scientific while avoiding that line.

Is it illegal for a cream to say it activates sirtuins?

It is allowed, and it carries risk. Lawyers in the field warn that claims about sirtuin activation, clearing senescent cells or repairing mitochondria can push a product into the drug category, which requires approval the product does not have.

Does a company-funded study mean the science is wrong?

No. It means you should read the affiliation and funding lines before the results, and check whether the paper reports an actual outcome in human skin or only describes a mechanism.

Has this happened before?

Yes. In 2014 the FTC settled with L'Oréal over gene-related anti-aging advertising for Lancôme Génifique and L'Oréal Paris Youth Code. The vocabulary then was genetics. It is now longevity.

References

  1. Valloppillil S, "Longevity is the beauty industry's most powerful claim and its weakest link," Fortune, 11 November 2026. Commentary. Source of the Harrison and Barzilai quotes and of the company examples.
  2. Kala R, Rella A, Eagle W, Goyarts E, Cao J, Deng B, Dong K, Schmit C, Cappock M, Corallo K, Trivero J, "Role of Sirtuins in the Hallmarks of Skin Aging," Aging Cell, November 2026. All eleven authors are employees of The Estée Lauder Companies, which the paper states in its conflict of interest declaration.
  3. FDA warning letter to Lancôme USA, a division of L'Oréal, 7 September 2012, citing claims including that a product boosts the activity of genes, and concluding that such claims make the products drugs under the Federal Food, Drug and Cosmetic Act. Reported at the time by Dermatology Times.
  4. Federal Trade Commission, "L'Oréal Settles FTC Charges Alleging Deceptive Advertising for Anti-Aging Cosmetics," 30 June 2014, an administrative consent order with no financial penalty. Summarised by Arent Fox Schiff.
  5. L'Oréal, "Beauty at the heart of longevity", the company's own description of the Longevity AI Cloud and its more than 260 skin longevity biomarkers.

The two primary government documents, the FDA warning letter and the FTC press release, are on fda.gov and ftc.gov under the titles and dates given above. They are linked here through secondary coverage because both sites block automated checking, and an unverified link is worse than none.